The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumab.
Beta 1-selective
Beta-blockers
Immunotherapy
Lung cancer
NSCLC
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
06 Dec 2023
06 Dec 2023
Historique:
received:
24
05
2023
revised:
15
11
2023
accepted:
03
12
2023
pubmed:
9
12
2023
medline:
9
12
2023
entrez:
8
12
2023
Statut:
aheadofprint
Résumé
Immune checkpoint inhibitors (ICIs) such as pembrolizumab have revolutionized the treatment of metastatic non-small cell lung cancer (mNSCLC). Beta-adrenergic activation contributes to cancer initiation and progression. While non-selective beta-blocker were found to improve the efficacy of ICIs therapy, the role of beta-1 (β To evaluate the effect of β We performed a retrospective analysis of patients diagnosed with mNSCLC and treated with first-line pembrolizumab at our center. Of 200 eligible patients, 53 (27%) were pretreated with β The use of baseline β
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) such as pembrolizumab have revolutionized the treatment of metastatic non-small cell lung cancer (mNSCLC). Beta-adrenergic activation contributes to cancer initiation and progression. While non-selective beta-blocker were found to improve the efficacy of ICIs therapy, the role of beta-1 (β
OBJECTIVE
OBJECTIVE
To evaluate the effect of β
METHODS
METHODS
We performed a retrospective analysis of patients diagnosed with mNSCLC and treated with first-line pembrolizumab at our center.
RESULTS
RESULTS
Of 200 eligible patients, 53 (27%) were pretreated with β
CONCLUSIONS
CONCLUSIONS
The use of baseline β
Identifiants
pubmed: 38065325
pii: S0167-5273(23)01777-1
doi: 10.1016/j.ijcard.2023.131642
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
131642Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.